IFN can be produced by various cells in the tumor microenvironment and has been reported to augment innate immune reactions through the MDA5 and protein kinase R (PKR) pathways.5 However, its frequent therapeutic resistance limits its further application. This evidence concerns the gene EIF2AK2 and neoplasm.